Created On: 2020-07-15
Record Count: 9
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 266792
With this agreement, the Parties wish to resolve all existing and potential claims and outstanding obligations in connection with All Litigation Matters and desire to settle All Litigation Matters on the terms stated herein, without any admission of liability or wrongdoing, in order to avoid the time and expense of continuing to litigate All Litigation Matters.
Cetuximab is an antibody for use in combination with irinotecan in the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, metastatic colorectal cancer who are refractory to irinotecan-based chemotherapy and for use as a single-agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy.
11F8 is a fully-human monoclonal antibody which targets the human EGFR.
__-72000, also known as matuzumab, is a humanized EGFR-targeting monoclonal antibody.
IPSCIO Record ID: 28041
IPSCIO Record ID: 260461
With this amendment, Licensor shall consent in writing to a grant by Licensee of Germany to a Third Party of a sub-license under the Radiotherapy Patent, the Chemotherapy Patent, each defined in the DLA and the Licensor Confidential Manufacturing Information, as defined in this July 2006 amendment to the DLA, to make, use and sell EMDâ€¢72000 which is a Licensee product, within the Territory.
With this amendment Licensor grants an irrevocable, non- exclusive, worldwide license to use the Licensor Confidential Manufacturing Information to manufacture Licensee Products.
Licensee Confidential Manufacturing Information shall mean any and all Licensee information that is reasonably useful for the production, manufacture, processing, filling, finishing. packaging, labeling, shipping, and storage of IMC-11F8.
The Licensee patents are titled Application entitled Pharmaceutical Preparation Comprising an Antibody Against the EGF Receptor; Application entitled Lyophilised Preparation Comprising Antibodies Against the EGF Receptor; Application entitled Liquid Formulation Comprising Cetuximab and Fatty Add Ester of Poiyoxyethylene Sorbitan; Application entitled Highly Concentrated Liquid Formulations of Antiâ€¢EGFR Antibodies; Application entitled Solid Forms of Anti-EGFR Antibodies; Application entitled Treatment of Refractory Human Tumors with Epidermal Growth Factor Receptor Antagonists, assigned to ImClone Systems Incorporated; Application entitled Treatment of Refractory Human Tumors with Epidermal Growth Factor Receptor; Antagonists, assigned to ImClone Systems Incorporated; Application entitled Method of Producing an Antibody to Epidermal Growth Factor Receptor, assigned to Licensor; Application entitled Hypeiprolifera Disease with Epidermal Growth Factor Receptor Antagonists, Assigned to Licensor; Application entitled Crystal of EGFR Extracellular Domain and Ceruximab Fab Fragment. and Uses Thereof, co-assigned to Licensor and University of Pennsylvania; and, Application entitled Method of Treating the Accumulation of Serous Fluids.
IPSCIO Record ID: 26106
The sharing of profit/loss reflects the co-exclusive rights to Erbitux in Japan previously granted by the Licensor to the Licensee and Bristol-Myers Squibb. Cetuximab Erbitux is a chimeric mouse/human monoclonal antibody used to treat metastatic colorectal cancer and head and neck cancer.
IPSCIO Record ID: 256273
This agreement includes a non-exclusive grant by Licensee to Licensor.
The patents include Novel Method for the Production of anti-human Antigen Receptors and Uses thereof, and, Anti-EpCAM Immunoglobulins.
Decatumumab (MT201) is a recombinant human monoclonal antibody with a binding specificity to epithelial cell adhesion molecule (Ep-CAM). Adecatumumab (MT201) is being evaluated in two European Phase 2 clinical trials, one in patients with prostate cancer, and one in patients with metastatic breast cancer.
IPSCIO Record ID: 256253
Licensor grants the French Licensee an exclusive right and license, with the right to grant sub licenses, under Licensed Technology and Licensed Patent Rights, including Licensors rights to Joint Technology and Joint Patent Rights, to research, have researched, develop, have developed, make, have made, use, offer for sale, sell, have sold, import and export Collaboration Compounds and Licensed Products in the Field in the Territory.
This agreement includes a non-exclusive grant-back from Licensee to Licensor.
MM-121 is a monoclonal antibody designed to block signaling of the ErbB3 receptor, a member of the epidermal growth factor (EGF) receptor family.
The Collaboration Compound means MM121, or, any antibody fragment of MM-121, including any Fab, F(ab)2, Fv, and scFv fragments, or the primary molecular target of which is ErbB3. ErbB3, also known as HER3, is a transmembrane receptor belonging to the epidermal growth factor (EGF) receptor family.
MM-121 is currently in Phase 1 clinical testing.
Licensed Technology means the Diagnostic Technology and the Therapeutic Technology.
MM-121 a genetically engineered antibody designed to block a receptor on cells known as ErbB3. Thatâ€™s thought to be an important new target for cancer drugs, because itâ€™s a member of the epidermal growth factor receptor family of proteins, which are known to amplify cell proliferation that can give rise to out-of-control tumors.
The ErbB3 receptor is a novel target known to be a key mediator of signaling in the ErbB pathway (also known as the EGFR or HER pathway) â€“ a signaling network that impacts a broad array of cancers. By targeting ErbB3, MM-121 is believed to have a broad application across cancer as both a monotherapy and in combination with other therapeutics.
IPSCIO Record ID: 257475
The FDA has approved MM-398 (irinotecan liposome injection; Onivyde) in combination with 5-fluorouracil (5-FU) and leucovorin as a treatment for patients with metastatic pancreatic cancer following prior administration of a gemcitabine-based regimen.
IPSCIO Record ID: 278110
Licensor granted the perpetual, non-exclusive rights to certain intellectual property, including diagnostic data related to VeriStrat, with respect to the development and commercialization of ficlatuzumab.
VeriStratÂ®, is Licensorâ€™s proprietary companion diagnostic test.
A retrospective exploratory analysis uses VeriStratÂ®, a commercially available serum protein test, to identify patients most likely to benefit from the addition of ficlatuzumab, AVEOâ€™s HGF inhibitory antibody, to epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy in a randomized Phase 2 study of ficlatuzumab and gefitinib (IRESSAÂ®) in previously untreated Asian subjects with non-small cell lung cancer (NSCLC).
IPSCIO Record ID: 255299
MGD013 is a first-in-class bispecific DART molecule designed to provide coordinate blockade of two immune checkpoint molecules expressed on T cells, PD-1 and LAG-3, for the potential treatment of a range of solid tumors and hematological malignancies.